


### In the Claims

Please amend claims 1, 3 and 26 as follows.

1. (Currently Amended) A method to treat multiple myeloma in a mammal, said method comprising contacting mammalian cancer cells with an amount of a compound of formula (I):



wherein R<sup>1</sup> is lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl or benzyl, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are the same or different and are each hydrogen or lower alkyl; R<sup>6</sup> is hydrogen, lower alkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R<sup>7</sup> is hydrogen, lower alkyl or lower alkenyl; X is oxy; Y is carbonyl or (C<sub>1</sub>-C<sub>3</sub>)alkyl(CO), wherein each alkyl is substituted with 0-2 (C<sub>1</sub>-C<sub>4</sub>) alkyl, and Z is hydroxy, lower alkoxy, amino, lower alkylamino, di(lower)alkylamino or phenylamino, or a pharmaceutically acceptable salt thereof, effective to kill cancerous bone marrow cells and to achieve a plasma level of the compound in the mammal of about 250 μM to 800 μM.

2. (Canceled).
3. (Currently amended) The method of claim 1 wherein the ~~mammalian cancer cells~~ human cancer cells mammal is a human.
4. (Previously Presented) The method of claim 3, wherein the compound of formula (I) is administered to a human cancer patient.

5-10 (Canceled).

11. (Previously Presented) The method of claim 3, wherein the compound of formula (I) is 1-R-(-) etodolac.

12. (Canceled).

13. (Previously Presented) The method of claim 4, wherein the compound of formula (I) is administered orally.

14. (Previously Presented) The method of claim 11, wherein the 1-R-(-) etodolac is administered orally.

15-25 (Canceled).

26. (Currently Amended) A method of treating multiple myeloma comprising administering to a human patient afflicted therewith an amount of 1-R-(-) etodolac effective to achieve a plasma level of the compound in the human patient of about 250  $\mu$ M to about 800  $\mu$ M, and to kill cancerous multiple myeloma cells, while maintaining the viability of normal bone marrow cells.

27. (Previously Presented) The method of claim 26, wherein the 1-R-(-) etodolac is administered orally.

28. (Original) The method of claim 26 wherein a daily dosage of about 1000-5000 mg of 1-R-(-) etodolac is administered.

29. (Original) The method of claim 28 wherein the plasma concentration of etodolac is about 500-700  $\mu$ M.

30-33 (Cancelled).

34. (Previously Presented) The method of claim 4, wherein the compound of formula (I) is etodolac.

35. (Previously Presented) The method of claim 1, wherein the compound of formula (I) is an 1-(R) enantiomer.